Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group LtdfiledCriticalBeecham Group Ltd
Publication of BE807933ApublicationCriticalpatent/BE807933A/en
C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
Chemical & Material Sciences
(AREA)
Organic Chemistry
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Title novel cpds of formula (I): (where R1 is H, MeCO or EtCO; R2 is 2-12C alkyl or alkenyl or a 5-membered heteroaromatic ring, pref. 2-thineyl or 2-furyl) are pref. prepd by reacting aminocyanoacetamide with Y-CR2=NH (where Y is a nucleophilically substitutable gp., esp. PhCH2S).
BE138277A1972-12-011973-11-285-Amino-4-carbamoylimidazoles - useful as injectable anti-inflammatory agents
BE807933A
(en)